Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01855880 · ClinicalTrials.gov registry record · Phase 2
Phase IIa Study of Multiple Doses of AbGn-168H by iv Infusion in Moderate to Severe Chronic Plaque Psoriasis Patients
A Phase 2 study of Moderate-to-severe Chronic Plaque Psoriasis, sponsored by AbGenomics B.V Taiwan Branch.
- Completed
- Registry status
- Phase 2
- Development phase
- 54
- Enrollment target
- 15
- Study locations
NCT01855880: Completed Phase 2 study of Moderate-to-severe Chronic Plaque Psoriasis, sponsored by AbGenomics B.V Taiwan Branch.
NCT01855880 is a Phase 2 study of Moderate-to-severe Chronic Plaque Psoriasis that has completed, run by AbGenomics B.V Taiwan Branch. The registered enrollment target is 54 participants, below the 210-participant average among 3 other Moderate-to-severe Chronic Plaque Psoriasis trials with a reported enrollment target (74% lower). The trial reports 15 study locations across 9 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01855880, a Phase 2 study of Moderate-to-severe Chronic Plaque Psoriasis, has completed, sponsored by AbGenomics B.V Taiwan Branch.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 54 participants
- Enrollment target
- 15
- Study locations
Study Summary
This is a Phase IIa, randomised, double-blind, placebo-controlled, multiple dose, multi-center study of AbGn-168H in subjects with moderate to severe chronic plaque psoriasis.The objectives of this study is to investigate efficacy, safety, tolerability, and pharmacokinetics (PK) of multiple doses of AbGn-168H administered intravenously to patients with moderate to severe chronic plaque psoriasis.
Primary Outcome
The primary objective of this study is to investigate efficacy (clinical proof of concept) of AbGn-168H in patients with moderate to severe chronic plaque psoriasis following intravenous administration of multiple doses compared to placebo. In this trial, the high dose and low dose of AbGn-168 and placebo is administered weekly.
Conditions Studied
Interventions
- BIOLOGICAL placebo
- BIOLOGICAL AbGn-168H
Study Locations (15)
Florida
- Visions Clinical Research - Boynton Beach
- Renstar Medical Research - Ocala
- Progressive Medical Research - Orange
- Olympian Clinical Research - Tampa
Arkansas
- Baptist Health Certer for Clinical Research - Little Rock
- Northwest AR Clinical Trials - Rogers
Indiana
- DawesFretzin Clinical Research Group, LLC. - Indianaopoli
- Indiana University Dermatology - Indianapolis
New York
- University Urology Associates & Manhattan Research Associates - New York
- Mount Sinai School of Medicine - New York
New Jersey
- Comprehensive Clinical Research - Berlin
Oklahoma
- Research Affiliation - Oklahoma City
South Carolina
- Radiant Research, Inc. - Greer
Texas
- Suzanne Bruce and Associates, The Center for Skin Research - Huston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 54 participants |
| Start Date | 2013-05 |
| Est. Completion | 2014-03 |
| Phase | Phase 2 |
What the finished NCT01855880 record still lists
NCT01855880 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 54 participants, a relatively small participant target, below the 210-participant average among 3 other Moderate-to-severe Chronic Plaque Psoriasis trials with a reported enrollment target (74% lower).
The record links to 1 condition, with Moderate-to-severe Chronic Plaque Psoriasis appearing as the primary indexed condition, and to 2 interventions - of which placebo is the first listed.
NCT01855880 lists 15 locations in 9 states (Florida, Arkansas, Indiana).
Frequently Asked Questions
What is clinical trial NCT01855880 about?
NCT01855880 is a clinical study titled "Phase IIa Study of Multiple Doses of AbGn-168H by iv Infusion in Moderate to Severe Chronic Plaque Psoriasis Patients". This is a Phase IIa, randomised, double-blind, placebo-controlled, multiple dose, multi-center study of AbGn-168H in subjects with moderate to severe chronic plaque psoriasis.The objectives of this study is to investigate efficacy, safety, tolerability, and pharmacokinetics (PK) of multiple doses of...
What is the current status of trial NCT01855880?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 54 participants. The study started on 2013-05. Estimated completion is 2014-03.
What conditions does trial NCT01855880 study?
This clinical trial studies the following conditions: Moderate-to-severe Chronic Plaque Psoriasis.
What interventions are being tested in trial NCT01855880?
The interventions under investigation include: placebo (BIOLOGICAL), AbGn-168H (BIOLOGICAL).
Who is sponsoring clinical trial NCT01855880?
This trial is sponsored by AbGenomics B.V Taiwan Branch, which has 6 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01855880 being conducted?
This trial has 15 study locations across Arkansas, Florida, Indiana, New Jersey, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Moderate-to-severe Chronic Plaque Psoriasis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study of Tildrakizumab in Pediatric Subjects With Chronic Plaque Psoriasis
ACTIVE NOT RECRUITING · Phase 2
-
A Study to Evaluate the Safety and Effectiveness of Doxercalciferol Capsules in Participants With Moderate to Severe Psoriasis
COMPLETED · Phase 2
-
Comparing Efficacy and Safety of Bmab 1200 and Stelara in Patients With Moderate to Severe Chronic Plaque Psoriasis
COMPLETED · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01269853 · 54 participants · Phase 1
Repeated Super-selective Intraarterial Cerebral Infusion of Bevacizumab (Avastin) for Treatment of Relapsed GBM and AA
- NCT02390752 · 54 participants · Phase 1
Phase I Trial of TURALIO(R) (Pexidartinib, PLX3397) in Children and Young Adults With Refractory Leukemias and Refractory Solid Tumors Including Neurofibromatosis Type 1 (NF1) Associated Plexiform Neurofibromas (PN) and Tenosynovial Giant Cell Tumor ...
- NCT02991248 · 54 participants · NA
Improve Dynamic Lateral Balance of Humans With SCI
- NCT02993900 · 54 participants · NA
Image-Guided Gynecologic Brachytherapy
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia